Latest Restenosis Stories

InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group

2013-05-23 08:26:36

Company to Host Conference Call Today at 8:00am ET, 2:00pm CET PARIS, May 23, 2013 /PRNewswire/ -- InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR), the leader in embolic protection stents, today announced new 6-month results from the MASTER (MGuard for Acute ST Elevation Reperfusion) trial demonstrating that the MGuard Embolic Protection Stent (EPS) outperformed bare metal and drug eluting stents in all-cause mortality in ST segment elevation myocardial...

Boston Scientific Promus PREMIER(TM) And SYNERGY(TM) Drug-Eluting Stent Systems Provide Exceptional Safety And Efficacy Data

2013-05-22 08:29:49

PARIS, May 22, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) reports positive results from two trials evaluating new, innovative drug-eluting stent (DES) technologies, which are emerging treatment options for coronary heart disease. Data from the first human use NG PROMUS Clinical Trial evaluating the safety and effectiveness of the Promus PREMIER(TM) Everolimus-Eluting Platinum Chromium Coronary Stent System, and two-year follow-up data from the EVOLVE Trial...

Allegheny General Hospital Cardiovascular Institute Becomes Exclusive Pittsburgh Site for Study of Novel Coronary Artery Disease Device

2013-05-20 23:19:09

Allegheny General Hospital (AGH) in Pittsburgh has been selected to join the ABSORB III clinical trial, a multi-center international study exploring a unique bioresorbable vascular scaffold (BVS), a small mesh tube that is designed to open a blocked artery and then fully dissolve over time, leaving the vessel free of a permanent metallic implant. The FDA-approved study of the drug-eluting AbsorbTM BVS, made by healthcare company Abbott, is expected to enroll approximately 2,250 patients...

OrbusNeich's Genous(TM) Stent Associated With Lower Restenosis Rate Compared to Bare Metal Stents in Low-Risk Non-ST-Segment Elevation Acute Coronary Syndrome (NSTE-ACS) Patients

2013-05-20 04:20:50

Results of Randomized JACK-EPC Trial Published in Minerva Cardioangiologica HONG KONG, May 20, 2013 /PRNewswire/ -- OrbusNeich today announced that the company's Genous Stent is associated with a significantly lower rate of binary restenosis compared to bare metal stents (BMS) in low-risk non-ST-segment elevation acute coronary syndrome (NSTE-ACS) patients at six months. Data from JACK-EPC, an investigator-initiated randomized study, were published in the June issue of Minerva...

InspireMD to Announce Six-Month Results from the MGuard(TM) Embolic Protection Stent (EPS) MASTER Trial at EuroPCR

2013-05-16 20:22:40

BOSTON and TEL AVIV, Israel, May 16, 2013 /PRNewswire/ -- -Strong Conference Presence to Include Presentations/Educational Events Featuring the MGuard(TM) Embolic Protection Stent- - Company to Host Conference Call on Thursday, May 23rd to Review MASTER Data - InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR), the leader in embolic protection stents, today announced a...

COMBO Dual Therapy Stent(TM) Clinical Results to Be Featured at EuroPCR 2013

2013-05-13 08:29:14

Results Will Be Presented During Symposium "Clinical Value of Anti-Restenosis and Pro-Healing COMBO Stent" and Oral Scientific Sessions HONG KONG, May 13, 2013 /PRNewswire/ -- OrbusNeich today announced that clinical results for the COMBO Dual Therapy Stent will be featured during EuroPCR 2013. Michael Haude, M.D., of Medical Clinic I at the Lukaskrankenhaus in Neuss, Germany, will present results from REMEDEE (Randomized Evaluation of an abluMinal sirolimus coatED bio-Engineered...

Data Published in JACC: Cardiovascular Interventions Show that OrbusNeich's COMBO Dual Therapy Stent(TM) Reaches Primary Study Endpoint and Is Effective in Controlling Neointimal Proliferation

2013-04-16 12:27:17

Results from REMEDEE Confirm that the COMBO Stent Is Non-Inferior to DES HONG KONG, April 16, 2013 /PRNewswire/ -- OrbusNeich today announced that data from the REMEDEE (Randomized Evaluation of an abluMinal sirolimus coatED bio-Engineered stEnt) study published online in JACC: Cardiovascular Interventions demonstrated that the COMBO Dual Therapy Stent met the study's primary endpoint and was found to be effective in controlling neointimal proliferation. Specifically, the COMBO Stent...

Drug-Coated Stents Prevent Leg Amputation

2013-04-15 14:11:10

Minimally invasive procedure proves better than surgery when angioplasty fails in patients with severely blocked leg arteries Drug-eluting stents can keep clogged leg arteries open, preventing amputation of the leg, suggests research being presented at the Society of Interventional Radiology's 38th Annual Scientific Meeting in New Orleans. "Peripheral arterial disease (or PAD) is becoming increasingly prevalent due to our aging population and the obesity and diabetes epidemics," said...

Drug-coated stents prevent leg amputation

2013-04-14 12:21:15

Minimally invasive procedure proves better than surgery when angioplasty fails in patients with severely blocked leg arteries NEW ORLEANS, April 14, 2013 /PRNewswire-USNewswire/ -- Highlights Drug-eluting stents are highly effective in keeping clogged leg arteries open and in helping to prevent leg amputation, study shows. Many patients with severe peripheral arterial disease (PAD) are poor candidates for surgery. PAD affects 10-15 percent of North Americans age 65 and older...

Interventional Cardiology Devices Market is Expected to Reach USD 25.2 Billion Globally in 2018: Transparency Market Research

2013-02-19 04:22:57

ALBANY, New York, February 19, 2013 /PRNewswire/ -- According to a new market report published by Transparency Market Research (http://www.transparencymarketresearch.com) "Interventional Cardiology Devices Market (Bare Metal/Drug Eluting/Bio-absorbable Stents, PTCA Balloons, Scoring Balloons, Guidewires, Guiding Catheters, Angiography Catheters, IVUS, Balloon Inflation Devices) - Global Industry Analysis, Size, Share, Trends and Forecast, 2012 - 2018," the global market for...